Rhabdomyosarcoma fusion oncoprotein initially pioneers a neural signature in vivo

Insights

Pediatric rhabdomyosarcoma is driven by PAX3::FOXO1, which pioneers inaccessible chromatin. This interaction activates neural gene programs, revealing a critical event in tumor initiation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Developmental Biology

Background:

  • Fusion-positive rhabdomyosarcoma is an aggressive pediatric cancer.
  • The PAX3::FOXO1 fusion protein is the primary genetic driver.
  • Current understanding of its in vivo epigenetic mechanisms is limited, hindering therapeutic development.

Purpose of the Study:

  • To investigate how PAX3::FOXO1 interacts with chromatin in vivo.
  • To understand the epigenetic mechanisms and transcriptional consequences of PAX3::FOXO1 binding.
  • To identify potential therapeutic targets for rhabdomyosarcoma.

Main Methods:

  • Established a PAX3::FOXO1 zebrafish injection model.
  • Developed a semi-automated ChIP-seq normalization strategy.
  • Analyzed PAX3::FOXO1 genome binding, chromatin accessibility, and H3K27ac redistribution.

Main Results:

  • PAX3::FOXO1 pioneers inaccessible chromatin via partial/homeobox motif recognition.
  • PAX3::FOXO1 binding alters chromatin accessibility and redistributes H3K27ac.
  • Activated neural transcriptional programs and signatures were identified, mirroring clinical rhabdomyosarcoma profiles.

Conclusions:

  • Partial/homeobox motif recognition is a novel mode of PAX3::FOXO1 pioneer function.
  • Neural signatures represent a critical PAX3::FOXO1-driven tumor initiation event.
  • Findings offer new insights into rhabdomyosarcoma pathogenesis and potential therapeutic strategies.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.3K